Getinge announces date of 2014 Q2 report and conference call

Getinge will issue its Q2 report for 2014 on Tuesday, July 15th 2014 at 08:00
CET, followed by a conference call at 10:00 CET, hosted by Johan Malmquist, CEO,
and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference
call. Please see below details to join the conference:
Swedish dial in number: +46 (0) 8 5065 3938
UK dial in number: +44 (0)20 3427 1907
US dial in number: +1 646 254 3365
Participant passcode: 9813592

Agenda
09:45 Call in to the conference
10:00 Review of the Q2 report
10:20 Q&A
11:00 End of conference

A recorded version of the conference can be accessed for 5 working days on the
following number:
Sweden: +46 (0)8 5051 3897
UK: +44 (0)20 3427 0598
US: +1 347 366 9565
Code: 9813592

During the telephone conference a presentation will be held. To access the
presentation, please use this link:
http://www.livemeeting.com/cc/premconfeurope/join?id=9813592&role=attend&pw=pw53
4 
4

Alternatively enter the Live Meeting site and log into your meeting using the
Meeting ID and Password below:
Live Meeting: http://www.livemeeting.com/cc/premconfeurope/
Your Name: (Enter your name)
Web Meeting ID: 9813592
Web Meeting Password: pw5344

For more information, please contact:
Kornelia Rasmussen
Group Communications
Phone: +46 (0)10 335 5810
E-mail: kornelia.rasmussen@getinge.com

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.